4808 Results

People

  1. Travis
    Travis
  2. Berger
    Berger
  3. Hudis
    Hudis
  4. Ladanyi
    Ladanyi
  5. Arcila
    Arcila
  6. Reis-Filho
    Reis-Filho
  7. Weigelt
    Weigelt
  8. Giralt
    Giralt
  9. Levine
    Levine
  10. Motzer
    Motzer

Groups

  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)
  7. Department of Pathology and Laboratory Medicine (714)
  8. Hematologic Malignancies, Division of (683)
  9. Population Sciences Research Program (601)
  10. Sloan Kettering Institute Faculty (586)
  1. "2015"
Formats
  1. Journal Article (2716)
  2. Meeting Abstract (1680)
  3. Book Section (364)
  4. Conference Paper (26)
  5. Book Whole (19)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)

More Groups

People
  1. William Travis (102)
  2. Michael Berger (96)
  3. Clifford Hudis (85)
  4. Marc Ladanyi (79)
  5. Jedd Wolchok (68)
  6. Britta Weigelt (67)

More People

Years
  1. 2015 (4808)
Publications
  1. Journal of Clinical Oncology (475)
  2. Blood (224)
  3. Cancer Research (168)
  4. Modern Pathology (125)
  5. Laboratory Investigation (112)
  6. International Journal of Radiation Oncology, Biology, Physics (91)

More Publications

Publishers
  1. Elsevier Inc. (581)
  2. American Society of Clinical Oncology (508)
  3. Springer (380)
  4. Nature Publishing Group (301)
  5. American Association for Cancer Research (263)
  6. American Society of Hematology (228)

More Publishers

Results (4808)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial
    Meeting Abstract

    Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothe, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T. W.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC)
    Meeting Abstract

    Cortes, J.; Crown, J.; Awada, A.; Schmid, P.; Gianni, L.; Garcia-Estevez, L.; Martinez-Janez, N.; Chan, S.; Steinberg, J. L.; Blaney, M.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Outcomes of well-differentiated papillary peritoneal mesothelioma
    Meeting Abstract

    Nash, G.; Morris, M.; Krug, L.; Zauderer, M.; Rusch, V.; Cercek, A.
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
    Meeting Abstract

    George, S.; Motzer, R. J.; Hammers, H.; Redman, B.; Kuzel, T.; Tykodi, S. S.; Plimack, E.; Jiang, J.; Waxman, I.; Rini, B. I.
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx)
    Meeting Abstract

    Scher, H. I.; Kelvin, J.; Lu, D.; Louw, J.; Packer, D.; Bambury, R.; Rathkopf, D.; Schreiber, N.; Brennan, R.; Prigozhina, N.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy
    Meeting Abstract

    Glen, H.; Hsieh, J.; Michaelson, M. D.; Kim, H. J.; Sachdev, P.; Kadowaki, T.; Funahashi, Y.; Larkin, J.; Motzer, R.
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer
    Meeting Abstract

    Voss, M.; Gordon, M. S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E. L.; Cervantes, A.; Puzanov, I.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors
    Meeting Abstract

    Juric, D.; Rodon, J.; Bauer, T. M.; Wainberg, Z.; Tolaney, S.; Modi, S.; Martin, A. G.; Hengelage, T.; Melendez, M.; Choudhury, S.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save